© 2022 MJH Life Sciences and Center for Biosimilars®. All rights reserved.
© 2022 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
Joseph Park, PhD, is the senior manager of regulatory strategy and policy at Samsung Bioepis. Park obtained his PhD from the Korea Advanced Institute of Science and Technology.
September 15, 2022
As more biosimilars are granted interchangeability status, 2 representatives from Samsung Bioepis stop misinformation in its tracks by clarifying that the designation will primarily impact pharmacy dispensing instead of prescription habits.